These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16415705)

  • 1. Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial.
    Sepede G; De Berardis D; Gambi F; Campanella D; La Rovere R; D'Amico M; Cicconetti A; Penna L; Peca S; Carano A; Mancini E; Salerno RM; Ferro FM
    J Clin Psychopharmacol; 2006 Feb; 26(1):45-9. PubMed ID: 16415705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine augmentation in panic disorder: a case report.
    Chao I
    Pharmacopsychiatry; 2004 Sep; 37(5):239-40. PubMed ID: 15470803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study.
    Dannon PN; Iancu I; Grunhaus L
    Hum Psychopharmacol; 2002 Oct; 17(7):329-33. PubMed ID: 12415550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder.
    Pollack MH; Rapaport MH; Fayyad R; Otto MW; Nierenberg AA; Clary CM
    J Psychiatr Res; 2002; 36(4):229-36. PubMed ID: 12191627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder.
    Dannon PN; Iancu I; Lowengrub K; Gonopolsky Y; Musin E; Grunhaus L; Kotler M
    Clin Neuropharmacol; 2007; 30(6):326-34. PubMed ID: 18090457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Facing the fear--clinical and neural effects of cognitive behavioural and pharmacotherapy in panic disorder with agoraphobia.
    Liebscher C; Wittmann A; Gechter J; Schlagenhauf F; Lueken U; Plag J; Straube B; Pfleiderer B; Fehm L; Gerlach AL; Kircher T; Fydrich T; Deckert J; Wittchen HU; Heinz A; Arolt V; Ströhle A
    Eur Neuropsychopharmacol; 2016 Mar; 26(3):431-44. PubMed ID: 26837851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial.
    Bozzatello P; Rocca P; Uscinska M; Bellino S
    CNS Drugs; 2017 Sep; 31(9):809-819. PubMed ID: 28741044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole augmentation for a patient with partial remission of panic disorder.
    Harada T; Yamada K; Sakamoto K; Ishigooka J
    J Clin Psychopharmacol; 2009 Jun; 29(3):301-2. PubMed ID: 19440089
    [No Abstract]   [Full Text] [Related]  

  • 11. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.
    Pollack MH; Otto MW; Worthington JJ; Manfro GG; Wolkow R
    Arch Gen Psychiatry; 1998 Nov; 55(11):1010-6. PubMed ID: 9819070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sertraline treatment of panic disorder: response in patients at risk for poor outcome.
    Pollack MH; Rapaport MH; Clary CM; Mardekian J; Wolkow R
    J Clin Psychiatry; 2000 Dec; 61(12):922-7. PubMed ID: 11206597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of personality disorder on the treatment of panic disorder--comparison study.
    Prasko J; Houbová P; Novák T; Záleský R; Espa-Cervená K; Pasková B; Vyskocilová J
    Neuro Endocrinol Lett; 2005 Dec; 26(6):667-74. PubMed ID: 16380683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder.
    Ballenger JC; Wheadon DE; Steiner M; Bushnell W; Gergel IP
    Am J Psychiatry; 1998 Jan; 155(1):36-42. PubMed ID: 9433336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies.
    Sheikh JI; Londborg P; Clary CM; Fayyad R
    Int Clin Psychopharmacol; 2000 Nov; 15(6):335-42. PubMed ID: 11110009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial.
    Simon NM; Otto MW; Worthington JJ; Hoge EA; Thompson EH; Lebeau RT; Moshier SJ; Zalta AK; Pollack MH
    J Clin Psychiatry; 2009 Nov; 70(11):1563-70. PubMed ID: 19814948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzodiazepines versus placebo for panic disorder in adults.
    Breilmann J; Girlanda F; Guaiana G; Barbui C; Cipriani A; Castellazzi M; Bighelli I; Davies SJ; Furukawa TA; Koesters M
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD010677. PubMed ID: 30921478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients.
    Sharpley AL; Attenburrow ME; Hafizi S; Cowen PJ
    J Clin Psychiatry; 2005 Apr; 66(4):450-4. PubMed ID: 15816787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study.
    Pollack MH; Simon NM; Zalta AK; Worthington JJ; Hoge EA; Mick E; Kinrys G; Oppenheimer J
    Biol Psychiatry; 2006 Feb; 59(3):211-5. PubMed ID: 16139813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.